Edison Oncology's Orotecan®: A Brighter Future For The Treatment of Recurrent Pediatric Cancers

The medication, Orotecan®, is a novel oral formulation of irinotecan, an intravenous drug that has demonstrated efficacy in treating various pediatric and adult cancers.

Related Keywords

Cincinnati ,Ohio ,United States ,Washington ,Jeffrey Bacha ,Children National Hospital ,Duke Children Hospital Health Center ,Edison Oncology ,Duke Children ,Health Center ,Cincinnati Children ,National Hospital ,